{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T20:51:35Z","timestamp":1785617495600,"version":"3.56.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Parasite-mediated diseases like malaria and schistosomiasis are growing health problems worldwide and novel drug candidates are urgently needed. In this study, the <jats:italic>in-vitro<\/jats:italic> safety profile of steroid compound 1o (sc1o), effective against the parasites <jats:italic>Plasmodium falciparum<\/jats:italic> and <jats:italic>Schistosoma mansoni<\/jats:italic> with an IC<jats:sub>50<\/jats:sub> value of 5\u2009nM, was characterized. We assessed viability\/proliferation, apoptosis and cell cycle tests to determine the cytotoxic profile of sc1o in cancer cells. The mutagenic potential was determined with the AMES test. To identify off-target effects we investigated whether sc1o interacts with safety-relevant molecules such as cytochrome P450 (CYP) enzymes, phosphodiesterases (PDE), histone deacteylases (HDAC) and human ether-a-go-go related gene (<jats:italic>h<\/jats:italic>ERG). Furthermore, to predict the potential bioavailability of sc1o, its effect on Caco-2 cell barrier integrity, by measurement of the transepithelial electrical resistance (TEER), was determined. Sc1o at 25\u2009\u00b5M reduced cell viability, probably through cell-cycle arrest, but did not induce apoptosis in cancer cells. No adverse off-target effects nor mutagenic potential of sc1o were observed. Furthermore, sc1o did not disturb the integrity of the cell barrier, but exhibited low membrane permeability, apparently due to cell adherence. In conclusion, sc1o up to 10\u2009\u00b5M showed a good <jats:italic>in-vitro<\/jats:italic> safety profile.<\/jats:p>","DOI":"10.1038\/s41598-020-64382-w","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T10:02:48Z","timestamp":1588672968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["In-vitro safety and off-target profile of the anti-parasitic arylmethylaminosteroid 1o"],"prefix":"10.1038","volume":"10","author":[{"given":"Leonard","family":"Blum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2543-1643","authenticated-orcid":false,"given":"Sheraz","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ulsh\u00f6fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Henke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reimar","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Berneburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Trautmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2663-1858","authenticated-orcid":false,"given":"Joachim","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Geisslinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Parnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schiffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"64382_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1473-3099(06)70521-7","volume":"6","author":"P Steinmann","year":"2006","unstructured":"Steinmann, P., Keiser, J., Bos, R., Tanner, M. & Utzinger, J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 6, 411\u2013425, https:\/\/doi.org\/10.1016\/S1473-3099(06)70521-7 (2006).","journal-title":"Lancet Infect Dis"},{"key":"64382_CR2","doi-asserted-by":"publisher","first-page":"102051","DOI":"10.1016\/j.parint.2020.102051","volume":"75","author":"Anisuzzaman","year":"2020","unstructured":"Anisuzzaman & Tsuji, N. Schistosomiasis and hookworm infection in humans: Disease burden, pathobiology and anthelmintic vaccines. Parasitol Int 75, 102051, https:\/\/doi.org\/10.1016\/j.parint.2020.102051 (2020).","journal-title":"Parasitol Int"},{"key":"64382_CR3","unstructured":"WHO. Schistosomiasis. Fact sheet N\u00b0 115 (2015). (2015)."},{"key":"64382_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1051\/parasite\/2014059","volume":"21","author":"S Sinha","year":"2014","unstructured":"Sinha, S., Medhi, B. & Sehgal, R. Challenges of drug-resistant malaria. Parasite 21, 61, https:\/\/doi.org\/10.1051\/parasite\/2014059 (2014).","journal-title":"Parasite"},{"key":"64382_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nrd4573","volume":"14","author":"TN Wells","year":"2015","unstructured":"Wells, T. N., Hooft van Huijsduijnen, R. & Van Voorhis, W. C. Malaria medicines: a glass half full? Nat Rev Drug Discov 14, 424\u2013442, https:\/\/doi.org\/10.1038\/nrd4573 (2015).","journal-title":"Nat Rev Drug Discov"},{"key":"64382_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1517\/14656566.5.2.263","volume":"5","author":"J Utzinger","year":"2004","unstructured":"Utzinger, J. & Keiser, J. Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin Pharmacother 5, 263\u2013285, https:\/\/doi.org\/10.1517\/14656566.5.2.263 (2004).","journal-title":"Expert Opin Pharmacother"},{"key":"64382_CR7","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1517\/17460441.2.S1.S35","volume":"2","author":"SS Botros","year":"2007","unstructured":"Botros, S. S. & Bennett, J. L. Praziquantel resistance. Expert Opin Drug Discov 2, S35\u201340, https:\/\/doi.org\/10.1517\/17460441.2.S1.S35 (2007).","journal-title":"Expert Opin Drug Discov"},{"key":"64382_CR8","doi-asserted-by":"crossref","unstructured":"Mader, P., Rennar, G. A., Ventura, A. M. P., Grevelding, C. G. & Schlitzer, M. Chemotherapy for Fighting Schistosomiasis: Past, Present and Future. ChemMedChem 13, 2374-2389, doi:10.1002\/cmdc.201800572 (2018).","DOI":"10.1002\/cmdc.201800572"},{"key":"64382_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14478","volume":"8","author":"R Krieg","year":"2017","unstructured":"Krieg, R. et al. Arylmethylamino steroids as antiparasitic agents. Nat Commun 8, 14478, https:\/\/doi.org\/10.1038\/ncomms14478 (2017).","journal-title":"Nat Commun"},{"key":"64382_CR10","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","volume":"162","author":"JP Hughes","year":"2011","unstructured":"Hughes, J. P., Rees, S., Kalindjian, S. B. & Philpott, K. L. Principles of early drug discovery. Br J Pharmacol 162, 1239\u20131249, https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01127.x (2011).","journal-title":"Br J Pharmacol"},{"key":"64382_CR11","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1038\/nprot.2007.303","volume":"2","author":"I Hubatsch","year":"2007","unstructured":"Hubatsch, I., Ragnarsson, E. G. & Artursson, P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2, 2111\u20132119, https:\/\/doi.org\/10.1038\/nprot.2007.303 (2007).","journal-title":"Nat Protoc"},{"key":"64382_CR12","first-page":"391","volume":"76","author":"T Lynch","year":"2007","unstructured":"Lynch, T. & Price, A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 76, 391\u2013396 (2007).","journal-title":"Am Fam Physician"},{"key":"64382_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/med.21445","volume":"38","author":"S Kalyaanamoorthy","year":"2018","unstructured":"Kalyaanamoorthy, S. & Barakat, K. H. Development of Safe Drugs: The hERG Challenge. Med Res Rev 38, 525\u2013555, https:\/\/doi.org\/10.1002\/med.21445 (2018).","journal-title":"Med Res Rev"},{"key":"64382_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.cdd.4400476","volume":"6","author":"AG Porter","year":"1999","unstructured":"Porter, A. G. & Janicke, R. U. Emerging roles of caspase-3 in apoptosis. Cell death and differentiation 6, 99\u2013104, https:\/\/doi.org\/10.1038\/sj.cdd.4400476 (1999).","journal-title":"Cell death and differentiation"},{"key":"64382_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1177\/2472555218823171","volume":"24","author":"CB Moraes","year":"2019","unstructured":"Moraes, C. B. et al. Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform. SLAS Discov 24, 346\u2013361, https:\/\/doi.org\/10.1177\/2472555218823171 (2019).","journal-title":"SLAS Discov"},{"key":"64382_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00232-001-0182-2","volume":"188","author":"B Rothen-Rutishauser","year":"2002","unstructured":"Rothen-Rutishauser, B., Riesen, F. K., Braun, A., Gunthert, M. & Wunderli-Allenspach, H. Dynamics of tight and adherens junctions under EGTA treatment. J Membr Biol 188, 151\u2013162, https:\/\/doi.org\/10.1007\/s00232-001-0182-2 (2002).","journal-title":"J Membr Biol"},{"key":"64382_CR17","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.farmac.2005.08.008","volume":"60","author":"P Sharma","year":"2005","unstructured":"Sharma, P., Varma, M. V., Chawla, H. P. & Panchagnula, R. Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers. Farmaco 60, 884\u2013893, https:\/\/doi.org\/10.1016\/j.farmac.2005.08.008 (2005).","journal-title":"Farmaco"},{"key":"64382_CR18","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.2174\/1381612825666190618121553","volume":"25","author":"G Paudwal","year":"2019","unstructured":"Paudwal, G. et al. Recent Advances in Solid Dispersion Technology for Efficient Delivery of Poorly Water-Soluble Drugs. Curr Pharm Des 25, 1524\u20131535, https:\/\/doi.org\/10.2174\/1381612825666190618121553 (2019).","journal-title":"Curr Pharm Des"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64382-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64382-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64382-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T10:06:46Z","timestamp":1670321206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64382-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["64382"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-64382-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]},"assertion":[{"value":"28 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7534"}}